8-K: NextCure Presents Promising SIM0505 Phase 1 Data

NextCure announced positive Phase 1 data for its investigational drug SIM0505 at ASCO 2026, showing a 55% ORR in gynecologic cancers.

Summary

• NextCure presented Phase 1 dose escalation data for its investigational drug candidate SIM0505 at the ASCO 2026 conference.
• The data, with a cutoff of April 7, 2026, involved 59 cancer patients treated with SIM0505 at doses ranging from 1.6 mg/kg to 9.6 mg/kg.
• In gynecologic cancer patients (ovarian and uterine serous carcinoma) within therapeutic dose cohorts (4.8-8.0 mg/kg) with at least 12 weeks of follow-up, the Objective Response Rate (ORR) was 55% (11/20).
• Specifically, ovarian cancer patients showed a 52.9% ORR (9/17), and uterine serous carcinoma (USC) patients showed a 66.7% ORR (2/3).
• The safety profile was generally manageable, with Grade 1 and 2 treatment-emergent adverse events (TEAEs) predominantly hematological, nausea, and vomiting.
• Grade 3 and 4 TEAEs were also predominantly hematological and manageable without primary prophylaxis.
• Three treatment-related adverse events (TRAEs) led to dose discontinuation: Grade 2 interstitial lung disease (ILD), Grade 3 fungal pneumonia, and Grade 4 thrombocytopenia.
• NextCure estimates its existing cash, cash equivalents, and marketable securities will fund operations into the first quarter of 2027.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, with encouraging efficacy data for SIM0505 and a manageable safety profile, supporting continued development and providing a degree of financial stability into early 2027.

Positives

• Demonstrated a 55% Objective Response Rate (ORR) in gynecologic cancer patients (ovarian and USC) within therapeutic dose cohorts.
• Achieved a 52.9% ORR in ovarian cancer patients and a 66.7% ORR in USC patients.
• Responses were observed across a range of CDH6 expression levels.
• The safety and tolerability profile appears manageable, with predominantly Grade 1 and 2 TEAEs.
• Grade 3 and 4 TEAEs were manageable and did not require primary prophylaxis for hematological toxicities.
• The company believes its current cash position is sufficient to fund operations into Q1 2027.

Negatives

• Three treatment-related adverse events (TRAEs) led to dose discontinuation: Grade 2 ILD, Grade 3 fungal pneumonia, and Grade 4 thrombocytopenia.
• The company acknowledges that its cash sufficiency estimate is based on assumptions that may prove incorrect and could be exhausted sooner than expected.

Risks

• The company's cash sufficiency estimate into Q1 2027 is based on assumptions that may prove incorrect and could lead to earlier exhaustion of capital resources.
• Forward-looking statements are subject to substantial risks and uncertainties that could cause actual results to differ materially, including the timing, progress, and results of clinical trials, regulatory approvals, and commercialization.
• Potential risks include the identification, analysis, and use of biomarkers, drug product sourcing and manufacturing, and the protection of intellectual property.

Future Outlook

NextCure is initiating a dose optimization segment for SIM0505 in gynecologic cancers, focusing on platinum-resistant ovarian cancer (PROC). The company plans to combine US and China data for a fast and definitive proof of concept and is expanding trial sites globally. They anticipate an update on dose optimization in Q1 2027 and plan to initiate dose optimization in USC in Q4 2026. The company also provided an update on LNCB74 development, with trial progress expected in 2H 2026.

Management Comments

• "Positive Phase 1 data presented at ASCO 2026 validate our conviction in SIM0505 as a potential best-in-class CDH6-directed therapy for gynecologic cancers. Meaningful response rates at 12 weeks, alongside a manageable safety profile, give us strong confidence in this program and reinforce our enthusiasm for the ongoing dose optimization study. We believe SIM0505 has broad potential in gynecologic cancers and beyond, and these data put us on a solid track toward pivotal studies and our goal of bringing this treatment to patients."
• "Data presented at ASCO 2026 underscore the promise of our ADC platform and SIM0505, purpose-designed to deliver better efficacy, safety and tolerability, combining a carefully selected EC1 CDH6 epitope with our proprietary CPT116 topoisomerase payload. These results validate the science behind the SIM0505 construct and the accelerating pace of the global development program. Together with our partner, we remain deeply committed to advancing innovative medicines for patients facing hard-to-treat cancers."
• "The early response rates observed for SIM0505 at ASCO 2026 are encouraging, and I believe the safety profile is manageable in routine clinical practice. I am enthusiastic about this program and its potential to advance the standard of care in gynecologic cancers."

Industry Context

StockSavvy.ai notes that the presentation of Phase 1 data for SIM0505 at ASCO 2026 positions NextCure within the competitive landscape of antibody-drug conjugates (ADCs) targeting CDH6, a promising biomarker in gynecologic and other solid tumors. The reported ORR figures are encouraging, particularly in the context of platinum-resistant ovarian cancer and uterine serous carcinoma, where significant unmet needs exist. The company's focus on dose optimization and potential pivotal studies aligns with industry trends of advancing promising early-stage assets towards late-stage development.

Comparison to Industry Standards

• The reported Objective Response Rate (ORR) of 55% in gynecologic cancers for SIM0505 is notable when compared to historical response rates for platinum-resistant ovarian cancer (PROC), which can be as low as 10-25% for available therapies.
• The ORR for ovarian cancer (52.9%) and USC (66.7%) are presented in the context of these specific patient populations, which have historically poor prognoses and limited treatment options.
• The safety profile, particularly the management of Grade 3 and 4 hematological toxicities without primary prophylaxis, is a key consideration in ADC development and is being evaluated against industry benchmarks for similar drug classes.

Stakeholder Impact

• Shareholders: Positive data may lead to increased investor confidence, but the long-term cash runway remains a point of consideration.
• Patients: Potential for a new treatment option for gynecologic cancers, particularly ovarian and uterine serous carcinoma, with promising early efficacy.
• Healthcare Providers: Data provides insights into the efficacy and safety of SIM0505, informing potential future treatment decisions.

Next Steps

• Continue Phase 1 dose optimization study for SIM0505 in gynecologic cancers, focusing on platinum-resistant ovarian cancer (PROC).
• Expand trial sites for SIM0505 globally (US, China, Canada, and Europe).
• Combine US and China data for SIM0505 to establish proof of concept.
• Update on SIM0505 dose optimization in Q1 2027.
• Initiate dose optimization for SIM0505 in USC in Q4 2026.
• Provide an update on LNCB74 trial progress in 2H 2026.
• Engage with members of the investment community to discuss presentation materials.

Key Dates

Recommendation

The Phase 1 data for SIM0505 are encouraging, showing promising efficacy in difficult-to-treat gynecologic cancers and a manageable safety profile. The company's cash runway into Q1 2027 provides some stability. However, the drug is still in early-stage development, and significant hurdles remain, including dose optimization, pivotal trials, and regulatory approval. Therefore, a 'hold' recommendation is appropriate, awaiting further de-risking events.

Keywords

SIM0505, NextCure, CDH6, Antibody-Drug Conjugate, Gynecologic Cancer, Ovarian Cancer, Uterine Serous Carcinoma, ASCO 2026